- Blanco C, Alderson D, Ogburn E, et al. Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug Alcohol Depend. 2007;90(2-3):252-260. doi:10.1016/j.drugalcdep.2007.04.005
- Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2003-2013. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015. https://www.samhsa.gov/.../2013_Treatment_Episode_Data_Set_National.pdf.
- Center for Behavioral Health Statistics and Quality. Drug Abuse Warning Network: 2011: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration
- Jones CM, McAninch JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. Am J Prev Med. 2015;49(4):493-501. doi:10.1016/j.amepre.2015.03.040
- Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in Drug and Opioid Overdose Deaths—United States, 2000–2014. Centers for Disease Control and Prevention; 2016. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6450a3.htm?s_cid=mm6450a3_w. Accessed November 7, 2017.
- CDC WONDER. Multiple Cause of Death 1999-2021. Centers for Disease Control and Prevention, National Center on Health Statistics. Released January 2023. Accessed January 2023.
- Center for Behavioral Health Statistics and Quality. Results from the 2017 National Survey on Drug Use and Health: Detailed Tables. Rockville (MD): SAMHSA; 2018. https://www.samhsa.gov/data/report/2017-nsduh-detailed-tables. Accessed October 19, 2018.
- Centers for Disease Control and Prevention. Vital Signs: Overdoses of Prescription Opioid Pain Relievers --- United States, 1999--2008. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm. Accessed September 18, 2018.
- Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010;13(5):401-435.
- Daniulaityte R, Falck R, Carlson RG. "I'm not afraid of those ones just ‘cause they’ve been prescribed": Perceptions of risk among illicit users of pharmaceutical opioids. Int J Drug Policy. 2012;23(5):374-384. doi:10.1016/j.drugpo.2012.01.012
- Webster PC. Oxycodone class action lawsuit filed. CMAJ Can Med Assoc J. 2012;184(7):E345-E346. doi:10.1503/cmaj.109-4158
- Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of Prescription and Over-the-counter Medications and Dietary Supplements Among Older Adults in the United States. JAMA. 2008;300(24):2867. doi:10.1001/jama.2008.892
- Miech R, Johnston L, O’Malley PM, Keyes KM, Heard K. Prescription Opioids in Adolescence and Future Opioid Misuse. Pediatrics. 2015;136(5):e1169-e1177. doi:10.1542/peds.2015-1364
- Mack KA, Jones CM, Paulozzi LJ. Vital Signs: Overdoses of Prescription Opioid Pain Relievers and Other Drugs Among Women—United States, 1999–2010.; 2013:537-542. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6226a3.htm. Accessed January 31, 2018.
- Center for Behavioral Health Statistics and Quality. Results from the 2017 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.
- Miech R, Schulenberg J, Johnston L, Bachman J, O’Malley P, Patrick M. Monitoring the Future National Adolescent Drug Trends in 2017: Findings Released. Ann Arbor, MI: Institute for Social Research, The University of Michigan; 2017. https://monitoringthefuture.org/wp-content/uploads/2021/02/17drugpr.pdf. Accessed January 2, 2018.
- McCabe SE, West BT, Teter CJ, Boyd CJ. Medical and nonmedical use of prescription opioids among high school seniors in the United States. Arch Pediatr Adolesc Med. 2012;166(9):797-802. doi:10.1001/archpediatrics.2012.85
- Boyd CJ, Esteban S, Teter CJ. Medical and nonmedical use of prescription pain medication by youth in a Detroit-area public school district. Drug Alcohol Depend. 2006;81(1):37-45. doi:10.1016/j.drugalcdep.2005.05.017
- McCabe SE, Teter CJ, Boyd CJ. Illicit use of prescription pain medication among college students. Drug Alcohol Depend. 2005;77(1):37-47. doi:10.1016/j.drugalcdep.2004.07.005
- Young AM, Glover N, Havens JR. Nonmedical use of prescription medications among adolescents in the United States: a systematic review. J Adolesc Health Off Publ Soc Adolesc Med. 2012;51(1):6-17. doi:10.1016/j.jadohealth.2012.01.011
- Wang R, Chen L, Fan L, et al. Incidence and Effects of Polypharmacy on Clinical Outcome among Patients Aged 80+: A Five-Year Follow-Up Study. PloS One. 2015;10(11):e0142123. doi:10.1371/journal.pone.0142123
- Cotto JH, Davis E, Dowling GJ, Elcano JC, Staton AB, Weiss SRB. Gender effects on drug use, abuse, and dependence: a special analysis of results from the National Survey on Drug Use and Health. Gend Med. 2010;7(5):402-413. doi:10.1016/j.genm.2010.09.004
- CDC Vital Signs: Prescription Painkiller Overdoses: A growing epidemic, especially among women. Centers for Disease Control and Prevention. https://www.cdc.gov/vitalsigns/prescriptionpainkilleroverdoses/index.html. Published March 23, 2017. Accessed March 27, 2017.
- Ronan MV, Herzig SJ. Hospitalizations Related To Opioid Abuse/Dependence And Associated Serious Infections Increased Sharply, 2002-12. Health Aff Proj Hope. 2016;35(5):832-837. doi:10.1377/hlthaff.2015.1424
- Jones CM, Paulozzi LJ, Mack KA. Alcohol Involvement in Opioid Pain Reliever and Benzodiazepine Drug Abuse–Related Emergency Department Visits and Drug-Related Deaths—United States, 2010. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6340a1.htm. Accessed September 18, 2018.
- Pentel P. Toxicity of Over-the-Counter Stimulants. JAMA. 1984;252(14):1898-1903.
- Gutstein H, Akil H. Opioid Analgesics. In: Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; 2006:547-590.
- Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016.; 2016. https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm. Accessed September 18, 2018.
- Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145-161.
- Hart C, Ksir C. Drugs, Society, and Human Behavior. 15 edition. New York, NY: McGraw-Hill Education; 2012.
- Jones CM, Lurie PG, Throckmorton DC. Effect of US Drug Enforcement Administration’s Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing. JAMA Intern Med. 2016;176(3):399-402. doi:10.1001/jamainternmed.2015.7799
- Oxycodone: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a682132.html. Accessed September 18, 2018.
- Oxymorphone: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a610022.html. Accessed September 18, 2018.
- Cicero TJ, Ellis MS. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin. JAMA Psychiatry. 2015;72(5):424-430. doi:10.1001/jamapsychiatry.2014.3043
- O’Brien CP, Dackis C. Principles of the Pharmacotherapy of Addictive Disorders. In: Neurobiology of Mental Illness. Third. Oxford University Press; 2006.
- O’Brien CP. Drug Addiction and Drug Abuse. In: Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; 2006:607-627.
- Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington (DC): National Academies Press (US); 2011. https://www.ncbi.nlm.nih.gov/books/NBK91497/.
- Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276-286. doi:10.7326/M14-2559
- Hypnotics and Sedatives. In: Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; 2006.
- Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol Off J Am Coll Med Toxicol. 2013;9(2):155-162. doi:10.1007/s13181-013-0292-0
- Sellers EM. Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management. CMAJ Can Med Assoc J. 1988;139(2):113-120.
- Ciccarone D. Stimulant Abuse: Pharmacology, Cocaine, Methamphetamine, Treatment, Attempts at Pharmacotherapy. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056348/. Accessed September 18, 2018.
- Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654-2662. doi:10.1056/NEJMra1500587
- Santosh PJ, Sattar S, Canagaratnam M. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs. 2011;25(9):737-763. doi:10.2165/11593070-000000000-00000
- Corp SA, Gitlin MJ, Altshuler LL. A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder. J Clin Psychiatry. 2014;75(9):1010-1018. doi:10.4088/JCP.13r08851
- Westfall T, Westfall D. Adrenergic Agonists and Antagonists. In: Goodman & Gilman’s the Pharmacological Basis of Therapeutics. Vol 11. McGraw-Hill; 2006:237-295.
- McCabe SE, West BT. Medical and Nonmedical Use of Prescription Stimulants: Results From a National Multicohort Study. J Am Acad Child Adolesc Psychiatry. 2013;52(12):1272-1280. doi:10.1016/j.jaac.2013.09.005
- Schelle KJ, Faulmuller N, Caviola L, Hewstone M. Attitudes toward pharmacological cognitive enhancement—a review. Front Syst Neurosci. 2014;8. doi:10.3389/fnsys.2014.00053
- Caldwell JA, Caldwell JL. Fatigue in military aviation: an overview of US military-approved pharmacological countermeasures. Aviat Space Environ Med. 2005;76(7 Suppl):C39-C51.
- Hyman SE. Cognitive Enhancement: Promises and Perils. Neuron. 2011;69(4):595-598. doi:10.1016/j.neuron.2011.02.012
- Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med. 2015;372(22):2118-2126. doi:10.1056/NEJMsa1500439
- Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol Off J Calif Perinat Assoc. 2015;35(8):650-655. doi:10.1038/jp.2015.36
- National Center for Health Statistics. Amublatory Care Use and Physician Office Visits.
- Center for Drug Evaluation and Research. Safe Disposal of Medicines—Disposal of Unused Medicines: What You Should Know. https://www.fda.gov/drugs/safe-disposal-medicines/disposal-unused-medicines-what-you-should-know. Accessed September 18, 2018.
- Simon K, Worthy SL, Barnes MC, Tarbell B. Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety. Ther Adv Drug Saf. 2015;6(2):67-79. doi:10.1177/2042098615569726
- Maldonado R, Baños JE, Cabañero D. The endocannabinoid system and neuropathic pain. Pain. 2016;157 Suppl 1:S23-S32. doi:10.1097/j.pain.0000000000000428
- National Institute on Drug Abuse. Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition). Bethesda, MD: National Institutes of Health; 2012. Accessed January 31, 2018.
- Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063-2066. doi:10.1056/NEJMp1402780
- Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS) 2002 - 2012: National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. https://www.samhsa.gov/data/sites/default/files/TEDS2012N_Web.pdf.
- Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55-e63. doi:10.2105/AJPH.2015.302664
- Obama Administration Takes More Actions to Address the Prescription Opioid and Heroin Epidemic. https://obamawhitehouse.archives.gov/the-press-office/2016/07/05/obama-administration-takes-more-actions-address-prescription-opioid-and.
- Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947-1954. doi:10.1001/jamainternmed.2014.5302
- D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-1644. doi:10.1001/jama.2015.3474
- Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33-40. doi:10.1016/j.drugalcdep.2014.05.011
- Kinlock TW, Gordon MS, Schwartz RP, O’Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 2007;91(2-3):220-227. doi:10.1016/j.drugalcdep.2007.05.022
- Lee JD, Friedmann PD, Kinlock TW, et al. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016;374(13):1232-1242. doi:10.1056/NEJMoa1505409
- Darker C, Sweeney B, Barry J, Farrell MF, Donnelly-Swift E. Psychosocial interventions to reduce sedative use, abuse and dependence. Cochrane Database Syst Rev. /CD009652/ADDICTN_psychosocial-interventions-to-reduce-sedative-use-abuse-and-dependence. Accessed September 18, 2018.
- Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1-2):8-18. doi:10.1016/j.drugalcdep.2012.07.004
- Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2020. Admissions to and Discharges from Publicly Funded Substance Use Treatment Facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2022.